Simultaneous occurrence of lupus anticoagulant, factor VIII inhibitor and localized pemphigoid

1996 ◽  
Vol 51 (3) ◽  
pp. 250-251 ◽  
Author(s):  
Christine Biron ◽  
Luc Durand ◽  
Tarek Lemkecher ◽  
Jean Dauverchain ◽  
Laurent Meunier ◽  
...  
Keyword(s):  
Factor Viii ◽  
Lupus Anticoagulant ◽  
Simultaneous Occurrence ◽  
Factor Viii Inhibitor ◽  
Viii Inhibitor

New Method for Quantifying Lupus Anticoagulant

1996 ◽  
Vol 2 (4) ◽  
pp. 237-240
Author(s):  
Roy Speck
Keyword(s):  
Factor Viii ◽  
Confidence Level ◽  
Lupus Anticoagulant ◽  
Heparin Therapy ◽  
Factor Ix ◽  
New Method ◽  
Factor Viii Inhibitor ◽  
Single Factor ◽  
Viii Inhibitor

A method is presented using a new reagent containing propylgallate for the quantitative determina tion of lupus anticoagulant. The amount of an optimized phospholipid standard required by the clotting reaction was found to be 32-50 μg/ml at a 95% confidence level, with a mean of 41 μg/ml. This method eliminates the ef fect of heparin therapy, coumadin therapy, factor-VIII inhibitor, factor-IX inhibitor, and single-factor deficien cies that afflict presently used lupus anticoagulant screen ing and confirmatory procedures. Using this method, it should be possible to detect lupus anticoagulant in pa tients at a much lower level and follow the effect of ther apy on lupus anticoagulant.

Acquired factor VIII inhibitor and positive lupus anticoagulant testing on silica clotting time

2014 ◽  
Vol 37 (1) ◽  
pp. 139-141
Author(s):  
H.-W. Ip ◽  
C.-C. So ◽  
Y.-Y. R. Leung ◽  
J.-Y. Chan ◽  
P. Sin ◽  
...  
Keyword(s):  
Factor Viii ◽  
Lupus Anticoagulant ◽  
Factor Viii Inhibitor ◽  
Clotting Time ◽  
Viii Inhibitor ◽  
Acquired Factor Viii Inhibitor

scholarly journals Successful management of life-threatening hemorrhage in a patient with synchronous lupus anticoagulant and factor VIII inhibitor

2002 ◽  
Vol 36 (4) ◽  
pp. 853-855 ◽  
Author(s):  
Hans A. Brings ◽  
John K. Waas ◽  
Keith R. McCrae ◽  
Henry R. Baele ◽  
Jerry Goldstone
Keyword(s):  
Factor Viii ◽  
Lupus Anticoagulant ◽  
Factor Viii Inhibitor ◽  
Successful Management ◽  
Life Threatening ◽  
Viii Inhibitor

scholarly journals An Unusual Etiology for Elevation of Activated Partial Thromboplastin Time (aPTT) in SLE: Acquired Hemophilia and Lupus Anticoagulant

2013 ◽  
Vol 2013 ◽  
pp. 1-3 ◽  
Author(s):  
Srikanth Seethala ◽  
Nathaniel P. Collins ◽  
George Comerci
Keyword(s):  
Factor Viii ◽  
Partial Thromboplastin Time ◽  
Lupus Anticoagulant ◽  
Activated Partial Thromboplastin Time ◽  
Factor Viii Inhibitor ◽  
Activity Levels ◽  
First Line ◽  
Acquired Hemophilia ◽  
Viii Inhibitor ◽  
Work Up

A 60-year-old female who has a history significant for diabetes, depression, and rheumatoid arthritis presented with a progressively enlarging hematoma of the left upper extremity. She was found to have an enlarging hematoma and an isolated elevation of activated partial thromboplastin time (aPTT). Lab work-up revealed low factor VIII activity levels and inhibitor titers at 13.38 Bethesda units (BU). Dilute Russell’s viper venom time (dRVVT) revealed a lupus anticoagulant. Hemostasis was achieved with factor VIII inhibitor bypassing activity (FEIBA) and inhibitor eradication with-rituxan after the failure of first-line treatment with cyclophosphamide and prednisone.

Acquired Factor VIII Inhibitor Associated with a Prostatic Cancer: Simultaneous Occurrence and Healing

1995 ◽  
Vol 73 (02) ◽  
pp. 327-328 ◽  
Author(s):  
François Lionnet ◽  
Marc Pulik ◽  
Philippe Genet ◽  
Gérard Lucas ◽  
Jean-Pierre Sollet
Keyword(s):  
Factor Viii ◽  
Prostatic Cancer ◽  
Simultaneous Occurrence ◽  
Factor Viii Inhibitor ◽  
Viii Inhibitor ◽  
Acquired Factor Viii Inhibitor

Lupus anticoagulant preceded by factor VIII inhibitor

1991 ◽  
Vol 61 ◽  
pp. 81 ◽  
Author(s):  
F. Luise ◽  
V. Brancaccio ◽  
I. Antinolfi ◽  
A. Ciampa
Keyword(s):  
Factor Viii ◽  
Lupus Anticoagulant ◽  
Factor Viii Inhibitor ◽  
Viii Inhibitor

Acquired Haemophilia: Functional Study of Antibodies to Factor VIII

1981 ◽  
Vol 45 (03) ◽  
pp. 285-289 ◽  
Author(s):  
J P Allain ◽  
A Gaillandre ◽  
D Frommel
Keyword(s):  
Factor Viii ◽  
Functional Study ◽  
Factor Viii Inhibitor ◽  
Acquired Haemophilia ◽  
Viii Inhibitor ◽  
Kinetics Of ◽  
Antibody Function ◽  
Native Plasma

SummaryFactor VIII complex and its interaction with antibodies to factor VIII have been studied in 17 non-haemophilic patients with factor VIII inhibitor. Low VIII:C and high VIIIR.Ag levels were found in all patients. VIII:WF levels were 50% of those of VTIIRrAg, possibly related to an increase of poorly aggregated and electrophoretically fast moving VIIIR:Ag oligomers.Antibody function has been characterized by kinetics of VIII :C inactivation, saturability by normal plasma and the slope of the affinity curve. Two major patterns were observed:1) Antibodies from 6 patients behaved similarly to those from haemophiliacs by showing second order inhibition kinetics, easy saturability and steep affinity slope (> 1).2) Antibodies from other patients, usually with lower titres, inactivated VIII :C according to complex order kinetics, were not saturable, and had a less steep affinity slope (< 0.7). In native plasma, or after mixing with factor VIII concentrate, antibodies of the second group did not form immune complexes with the whole factor VIII molecular complex. However, dissociation procedures did release some antibodies from apparently low molecular weight complexes formed in vivo or in vitro. For appropriate management of non-haemophilic patients with factor VIII inhibitor, it is important to determine the functional properties of their antibodies to factor VIII.

A Higher than Expected Incidence of Factor VIII Inhibitors in Multitransfused Haemophilia A Patients Treated with an Intermediate Purity Pasteurized Factor VIII Concentrate

1993 ◽  
Vol 69 (02) ◽  
pp. 115-118 ◽  
Author(s):  
Kathelijne Peerlinck ◽  
Jef Arnout ◽  
Jean Guy Gilles ◽  
Jean-Marie Saint-Remy ◽  
Jos Vermylen
Keyword(s):  
Factor Viii ◽  
Randomized Trials ◽  
Specific Factor ◽  
Factor Viii Inhibitor ◽  
Haemophilia A ◽  
Viral Inactivation ◽  
Gradual Decline ◽  
Inhibitor Level ◽  
Factor Viii Concentrates ◽  
Viii Inhibitor

SummaryIn May 1990, 218 patients with haemophilia A regularly attending the Leuven Haemophilia Center were randomly assigned to a group receiving either of two newly introduced factor VIII concentrates: factor VIII-P, an intermediate purity pasteurized concentrate, or factor VIII-SD, a high purity concentrate treated with solvent-detergent for viral inactivation.Patients were followed from May 1990 until October 1991. Between August 1991 and October 1991 a clinically important factor VIII inhibitor was detected in five out of the 109 patients receiving factor VIII-P while none of the 109 patients receiving factor VIII-SD developed such antibodies. All patients acquiring an inhibitor had previously been clinically tolerant to transfused factor VIII with 200 to more than 1,000 days of exposure to factor VIII prior to May 1990. Patients with inhibitors were transfused daily with 30 U factor VIII-SD per kg body weight, which was associated with a gradual decline of the inhibitor level. In all patients the antibodies were relatively slow-acting and predominantly directed towards the light chain of factor VIII.This study demonstrates a higher than expected incidence of factor VIII inhibitors associated with the use of a specific factor VIII concentrate in multitransfused haemophilia A patients. It indicates the usefulness of evaluating newly introduced concentrates in prospective, randomized trials.

Sign in / Sign up

Export Citation Format

Share Document